Health Reform Roundup: More Delays, More On Comparative Effectiveness
This article was originally published in The Gray Sheet
Executive Summary
The timetable for passage of health care reform legislation grew more uncertain last week as the House Energy and Commerce Committee suspended markup of its bill after just one day's work
You may also be interested in...
Health Reform Roundup: A Week Of Ups And Downs For Democratic Effort
Three of the five involved committees in Congress approved comprehensive health care reform legislation last week, but it was still a week laden with barriers and delays to the overall goal of getting legislation to the president's desk
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.